Malignant Melanoma Clinical Trials
A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 22 clinical trials
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
A mucosal melanoma postoperative adjuvant treatment of multicenter, randomized, double-blind, placebo-controlled phase II study, evaluation of mucosal melanoma patients accept completely resected, Toripalima Combined with Temozolomide and Cisplatin postoperative adjuvant therapy efficacy and safety
- 0 views
- 05 Aug, 2020
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
This study is a multicenter, single-arm, open, phase clinical study to evaluate the safety and efficacy of Toripalimab(JS001) monoclonal injection after chemotherapy in combination with Endostar for Locally Advanced or Metastatic Mucosal Melanoma.
- 0 views
- 16 Feb, 2024
- 1 location
PHP and Immunotherapy in Metastasized UM
Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs.
- 0 views
- 16 Feb, 2024
- 1 location
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
This is a phase III randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb in combination with CTLA4 mAb for injection compared to high-Dose interferon in patients with acral melanoma that has been removed by surgery.
- 0 views
- 16 Feb, 2024
- 1 location
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the second part will include 3 expansion cohorts of 15 patients: B1: anti-PD-1 refractory advanced NSCLC cohort …
- 0 views
- 16 Feb, 2024
- 1 location
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.
- 0 views
- 05 Aug, 2020
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
- 0 views
- 16 Feb, 2024
- 4 locations
Neoadjuvant T-VEC in High Risk Early Melanoma
The investigators propose an open-label, Phase 2 study of talimogene laherparepvec (T-VEC), in the neoadjuvant setting for patients with high-risk, resectable primary and cutaneous melanoma prior to definitive excision. The central hypothesis of this proposal is that neoadjuvant intra-lesional therapy with T-VEC in high risk early stage melanoma will effectively …
- 0 views
- 16 Feb, 2024
- 1 location
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing on CPI treatment, CPI-nave HCC, and treatment-nave Endometrial.
- 0 views
- 16 Feb, 2024
- 9 locations
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications
This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.
- 0 views
- 05 Aug, 2020